[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353953-105":59,"doc-detail-353953-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","ifng-induced-antigen-loss-in-chimeric-antigen-receptor-t-cell-therapy-original-research-article","IFNg-induced antigen loss in chimeric antigen receptor-T cell therapy - Original Research Article","","Mechanistic research investigates how colorectal cancer cells respond when exposed to activated chimeric antigen receptor T cell therapy. In vitro co-culture, conditioned media, cytokine screening, pharmacologic inhibition, CRISPR-Cas9 knockout, and transcriptomic analyses identify a previously uncharacterized GUCY2C antigen loss pathway. The study shows that IFNg secreted by CART cells drives bystander cancer cells to lose GUCY2C via IFNg receptor, JAK, and cellular stress signaling. Functional rescue is demonstrated with anti-IFNg neutralizing antibody, ruxolitinib, or ER stress relief, informing strategies to improve solid-tumor CART and BiTE efficacy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ifng-induced-antigen-loss-in-chimeric-antigen-receptor-t-cell-therapy-original-research-article/353953/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ifng-induced-antigen-loss-in-chimeric-antigen-receptor-t-cell-therapy-original-research-article/353953.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in CAR-T therapy for colorectal cancer?","Question",{"text":112,"@type":113},"It addresses why CAR-T cell therapies targeting solid tumors, including colorectal cancer, have limited efficacy and safety in clinical settings. The study focuses on mechanisms that reduce target antigen availability in CRC during CART treatment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does IFNg affect GUCY2C antigen expression in this therapy setting?",{"text":117,"@type":113},"IFNg secreted by activated CART cells causes nearby (bystander) cancer cells to lose GUCY2C. This creates an antigen-loss mechanism that limits CART efficacy in CRC.",{"name":119,"@type":110,"acceptedAnswer":120},"What interventions can rescue the antigen loss mechanism?",{"text":121,"@type":113},"The study reports that antigen loss can be rescued using an anti-IFNg neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate as an ER stress reliever.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353953,1790171020,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 17 March 2026  \nDOI 10.3389/fimmu.2026.1772472  \nOPEN ACCESS  \nEDITED BY  \nJeffrey J. Pu,  \nTufts University, United States  \nREVIEWED BY  \nYirong Sun,  \nChinese Academy of Sciences (CAS), China  \nPatricia Hernandez,  \nUniversity Medical Center Utrecht, Netherlands  \n*CORRESPONDENCE  \nAdam E. Snook  \n [adam.snook@jefferson.edu](adam.snook@jefferson.edu)  \nRECEIVED 21 December 2025  \nREVISED 20 February 2026  \nACCEPTED 24 February 2026  \nPUBLISHED 17 March 2026  \nCITATION  \nCao M, Alvarez J, Mitra R, Xu M, Baybutt TR, Sun Z, Taylor O, Doermann AS, Staudt RE, Waldman SA and Snook AE (2026) IFNg-induced antigen loss in chimeric antigen receptor-T cell therapy.  \nFront. Immunol. 17:1772472 .  \ndoi: 10.3389/fimmu.2026.1772472  \nCOPYRIGHT  \n© 2026 Cao, Alvarez, Mitra, Xu, Baybutt, Sun, Taylor, Doermann, Staudt, Waldman and Snook. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIFNg-induced antigen loss in chimeric antigen receptor-T cell therapy  \nMiao Cao 1, Jasmine Alvarez 1, Ramkrishna Mitra 1, Michael Xu 1, Trevor R. Baybutt 1, Zhengyang Sun 1, Oluwatobiloba Taylor 1, Allison S. Doermann 2, Ross E. Staudt 1, Scott A. Waldman 1 and Adam E. Snook 1*  \n1 Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA, United States, 2 Department of Surgery, Thomas Jefferson University, Philadelphia, PA, United States  \nIntroduction: FDA-approved chimeric antigen receptor (CAR)-expressing T cell therapies (CARTs) have revolutionized the treatment of blood cancers. Yet none have been successful for \"solid\" tumors, such as colorectal cancer (CRC), the 2nd leading cause of cancer deaths. Guanylyl cyclase C (GUCY2C) has emerged as a clinical-stage target for CART and bispeciﬁc T-cell engager (BiTE) therapies in CRC. IFNg has been canonically recognized as beneﬁcial for the effector functions of T cells by enhancing antigen processing and HLA presentation and is essential for CART targeting of solid malignancies by inducing adhesion molecule expression for synapse stabilization.  \nMethods: Using in vitro co-culture systems, conditioned media experiments, cytokine screening, pharmacologic inhibition, CRISPR-Cas9 knockout, and transcriptomic analyses, we investigated mechanisms of GUCY2C antigen loss in CRC cells exposed to activated CART cells.  \nResults: We identiﬁed a novel antigen loss mechanism that limits the efﬁcacy of CART in CRC, in which IFNg secreted by activated CART cells causes bystander cancer cells to lose GUCY2C. This previously unexplored antigen loss mechanism is mediated through IFNg receptor, JAK, and cellular stress signaling pathways. This mechanism of antigen loss can be rescued with anti-IFNg neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate (an ER stress reliever) . Discussion: We revealed a negative effect of IFNg that uniquely interferes with immunotherapies targeting native surface antigens, such as CART and BiTE therapies, which may be reversed by disrupting stress signaling pathways to enhance solid tumor CART and BiTE immunotherapies.  \nKEYWORDS  \nantigen escape, CAR-T cell, colorectal cancer, GUCY2C, IFNg, tumor microenvironment  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nImmunotherapy has been established as the 4th pillar of cancer care, in addition to surgery, chemotherapy, and radiotherapy (1, 2) . Immune checkpoint blockade (ICB) has signiﬁcantly impacted outcomes in lung cancer and melanoma, but its efﬁcacy in colorectal cancer (CRC) is limited to only a small percent","cbCaipISLNMRwMP4","https://ap.wps.com/l/cbCaipISLNMRwMP4","pdf",3822734,14,"English","# Introduction\n# Methods\n# Results\n# Discussion\n# Keywords","[{\"question\":\"What problem does the study address in CAR-T therapy for colorectal cancer?\",\"answer\":\"It addresses why CAR-T cell therapies targeting solid tumors, including colorectal cancer, have limited efficacy and safety in clinical settings. The study focuses on mechanisms that reduce target antigen availability in CRC during CART treatment.\"},{\"question\":\"How does IFNg affect GUCY2C antigen expression in this therapy setting?\",\"answer\":\"IFNg secreted by activated CART cells causes nearby (bystander) cancer cells to lose GUCY2C. This creates an antigen-loss mechanism that limits CART efficacy in CRC.\"},{\"question\":\"What interventions can rescue the antigen loss mechanism?\",\"answer\":\"The study reports that antigen loss can be rescued using an anti-IFNg neutralizing antibody, the JAK inhibitor ruxolitinib, or 4-phenylbutyrate as an ER stress reliever.\"}]","IFNg-induced antigen loss in chimeric antigen receptor-T cell therapy - Original Research Article | PDF",1790108098,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/95fac30e9e96076d97403836a7b682d8.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9555afc0ec45b9e017ce63ec49098b6d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/571a9a02a1cd77a2941b8235746bf121.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07b2c2e540fb55f05639f18edabf104a.webp",980,1385]